Alburx 25% Injection
Albumin Human 25%
25%
CSL Behring Ag, Switzeland
| Pack size | 50ml,100ml |
|---|---|
| Dispensing mode | |
| Source | |
| Agent | |
| Retail Price | 4500.00, 9000.00 AED |
Indications
Alburx 25% Injection is used for:
Hypovolemia, Ascites, Hypoalbuminemia including from burns, Acute Nephrosis, Acute Respiratory Distress Syndrome (ARDS), Cardiopulmonary Bypass
Adult Dose
Adult:
Intravenous
Initially, 25 g of albumin, was adjusted according to the patient's response. Usual rates of infusion: 1-2 ml/minute.
Hypovolemia
Initial dose of 25 g (including renal dialysis).
For acute liver failure: initial dose of 12 to 25 g.
Ascites
Prevention of central volume depletion after paracentesis due to cirrhotic ascites
8 g for every 1000 mL of ascitic fluid removed.
Hypoalbuminemia including from burns: 50 to 75 g
For pre- and post-operative hypoproteinemia: 50 to 75 g.
For burn therapy after the first 24 h: initial dose of 25 g and dose adjustment to maintain plasma protein concentration of 2.5 g per 100 mL.
Third space protein loss due to infection: initial dose of 50 to 100 g.
Acute Nephrosis
25 g together with diuretic once a day for 7-10 days.
Acute Respiratory Distress Syndrome (ARDS)
25 g over 30 minutes and repeated at 8 hours for 3 days, if necessary
Cardiopulmonary bypass procedures
The initial dose of 25 g.
Child Dose
Child: Up to 1 g/kg, adjusted according to patient's response. Usual rates of infusion: 1-2 ml/minute.
Not to exceed 250 g/48 hr or 6 g/kg/day
Hemolytic Disease of the Newborn
25% albumin: 1 g/kg/dose IV administered before or during plasma exchange
Use 25% concentration with extreme caution in neonates, owing to risk of intraventricular hemorrhage from rapid expansion of intravascular volume
Ascites with Hypoalbuminemia
25% albumin: 1 g/kg/dose IV infused over 2-3 hr; may repeat q8hr until serum albumin above 2.5 g/dL
Renal Dose
Administration
IV Preparation
Reconstitution: If 5% human albumin is unavailable, dilute 25% human albumin with NS or D5W
Do NOT use sterile water as diluent - risk of potentially fatal hemolysis and acute renal failure
IV Administration
For IV administration only
25% solution: Use in patients who have fluid or sodium restrictions, or to mobilize fluids
Use within 4 hr after opening vial; discard unused portion
Albumin 25% may be given undiluted or diluted in in 0.9% NaCl
May give in combination or through same administration set as saline or carbohydrates
Do not use with ethanol or protein hydrolysates; precipitation may form
Contra Indications
Hypersensitivity to human albumin or the excipients
Severe anemia or cardiac failure with normal or increased intravascular volume
Precautions
Suspicion of allergic or anaphylactic reactions requires immediate discontinuation of the injection and implementation of appropriate medical treatment.
Hypervolemia may occur if the dosage and rate of infusion are not adjusted to the patient’s volume status. Use with caution in conditions where hypervolemia and its consequences or
hemodilution could represent a special risk to the patient.
When concentrated albumin is administered, care must be taken to ensure adequate hydration of the patient.
Albumin is a blood product; extremely remote risk for transmission of viral diseases and variant Creutzfeldt-Jakob disease (vCJD)
Monitoring Parameters
Plasma and plasma substitutes are often used in very ill patients whose condition is unstable. Therefore, close monitoring is required and fluid and electrolyte therapy should be adjusted according to the patient’s condition at all times.
Monitor electrolyte status.
Monitor for signs of cardiac overload in injured or postoperative patients.
Monitor hemodynamic performance: this may include:
Arterial blood pressure and pulse rate
Central venous pressure
Pulmonary artery occlusion pressure
Urine output
Electrolytes
Hematocrit/hemoglobin.
Pregnancy-Lactation
Pregnancy
No human or animal data are available to indicate the presence or absence of drug-associated risk
Lactation
Unknown if excreted in human milk
Interactions
Do not mix with blood, blood components, protein hydrolysates, alcoholic solutions or other medicinal products except 0.9% saline or 5% dextrose. However, it can be administered, via a separate IV line, concomitantly with other parenterals.
Risk of atypical reactions to ACE inhibitors in patients undergoing therapeutic plasma exchange with albumin human replacement.
Adverse Effects
Side effects of Albumin Human 25% :
Frequency Not Defined
Flushing
Urticaria
Fever
Chills
Nausea
Vomiting
Tachycardia
Hypotension.
Potentially Fatal: Anaphylactic shock.
Mechanism of Action
Human albumin increases intravascular oncotic pressure and causes movement of fluids from interstitial into intravascular space. Human albumin solutions are available in various concentrations. Solutions containing 5% human albumin are usually used in hypovolemic patients, whereas more concentrated 25% solutions are recommended in patients in whom fluid and sodium intake must be minimised e.g. patients with hypoproteinaemia or cerebral oedema or in paediatric patients.
Note
Alburx 25% 25% Injection manufactured by CSL Behring Ag, Switzeland. Its generic name is Albumin Human 25%. Alburx 25% is availble in Bangladesh.
Farmaco BD drug index information on Alburx 25% Injection is not intended for diagnosis, medical advice or treatment; neither intended to be a substitute for the exercise of professional judgment.